Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Net Income (2016 - 2025)

Historic Net Income for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to -$180.4 million.

  • Ultragenyx Pharmaceutical's Net Income fell 3512.46% to -$180.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$581.2 million, marking a year-over-year decrease of 397.38%. This contributed to the annual value of -$570.6 million for FY2024, which is 594.82% up from last year.
  • Ultragenyx Pharmaceutical's Net Income amounted to -$180.4 million in Q3 2025, which was down 3512.46% from -$115.0 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Net Income ranged from a high of -$73.0 million in Q3 2021 and a low of -$245.1 million during Q3 2022
  • Its 5-year average for Net Income is -$146.9 million, with a median of -$151.1 million in 2025.
  • In the last 5 years, Ultragenyx Pharmaceutical's Net Income crashed by 58361.84% in 2021 and then soared by 3486.53% in 2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Net Income (Quarter) stood at -$124.8 million in 2021, then decreased by 24.34% to -$155.2 million in 2022, then increased by 20.6% to -$123.2 million in 2023, then decreased by 9.39% to -$134.8 million in 2024, then tumbled by 33.88% to -$180.4 million in 2025.
  • Its Net Income was -$180.4 million in Q3 2025, compared to -$115.0 million in Q2 2025 and -$151.1 million in Q1 2025.